Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Effects of estradiol administration on brain activation and anhedonia in perimenopausal women: A pharmaco-fMRI study.
J Affect Disord
January 2025
Department of Psychiatry, University of North Carolina at Chapel Hill, United States of America. Electronic address:
Background: Half of perimenopausal women experience depressive symptoms, including anhedonia. Anhedonia is associated with dysregulation of the frontostriatal circuit. Both the frontrostriatal circuit and depression may be regulated by the reproductive hormone estradiol (E2).
View Article and Find Full Text PDFStrategies to promote the provision of sexual health services during menopause: a qualitative study from the perspective of menopausal women and healthcare providers in Isfahan city, Iran.
BMC Health Serv Res
January 2025
Department of Midwifery and Reproductive Health, Faculty of Nursing and Midwifery, Isfahan University of Medical Sciences, Isfahan, Iran.
Background: It is important to care for the sexual function of women during menopause as it can affect their quality of life. However, the services related to this area have been neglected in the health system and are not provided at the desired level. Therefore, the present study aimed to identify strategies to promote the provision of sexual health services during menopause in Isfahan city, Iran.
View Article and Find Full Text PDFEffects of Lasofoxifene Versus Fulvestrant on Vaginal and Vulvar Symptoms in Patients With ESR1-Mutated, ER+/HER2-, Metastatic Breast Cancer From the ELAINE 1 Study.
Clin Breast Cancer
December 2024
Sermonix Pharmaceuticals, Columbus, OH.
Background: Lasofoxifene, a novel endocrine therapy (ET), showed antitumor activity versus fulvestrant in women with ESR1-mutated, metastatic breast cancer (mBC) that progressed on prior ET (phase 2, ELAINE 1 study). We investigated changes in genitourinary syndrome of menopause (GSM) vulvar-vaginal symptoms with lasofoxifene and how patient/disease characteristics affect baseline vulvar-vaginal symptoms in ELAINE 1.
Methods: Women were randomized to oral lasofoxifene 5 mg/day or IM fulvestrant 500 mg (days 1, 15, and 29, then every 28 days) until disease progression/severe toxicity.
Updates in nonhormonal therapy for perimenopausal and menopausal symptoms.
Curr Opin Obstet Gynecol
January 2025
Division of Complex Family Planning, Department of Obstetrics and Gynecology, Stanford University Medical Center, Stanford, California, USA.
Purpose Of Review: Perimenopausal and menopausal symptoms are common and may significantly impact quality of life. Menopausal hormone therapy is the most effective treatment but may not be appropriate in all cases. Nonhormonal alternatives range from lifestyle changes and dietary supplements to medical interventions and prescription therapies.
View Article and Find Full Text PDFPredictive and prognostic value of F-FES PET/CT for patients with recurrent or metastatic breast cancer treated with endocrine therapy plus cyclin-dependent kinase 4/6 inhibitors.
Eur J Nucl Med Mol Imaging
January 2025
Department of Nuclear Medicine, Asan Medical Center, University of Ulsan College of Medicine, 88, Olympic-Ro 43-Gil, Songpa-Gu, Seoul, 05505, Korea.
Purpose: Estrogen receptor (ER) expression and heterogeneity affect endocrine therapy efficacy. F-fluoroestradiol (F-FES) PET/CT is an effective non-invasive method to analyze systemic ER expression. This study aimed to examine the predictive/prognostic value of F-FES PET/CT for patients treated with endocrine therapy plus cyclin-dependent kinase 4/6 (CDK4/6) inhibitors.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!